CommercialCoverageMedium impact
08.01.14e, Radium Ra 223 dichloride (Xofigo®) Injection (Independence Administrators)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Mar 4, 2026
We identified it
Jun 19, 2026
Summary
Independence Administrators has reissued the policy for Radium Ra 223 dichloride (Xofigo®) injection, a specialized cancer treatment drug. This is a pharmacy policy update that will take effect March 4, 2026, indicating potential changes to coverage, prior authorization, or billing requirements for this oncology medication.
Action Required
By March 4, 2026: Oncology billing team should review the updated Radium Ra 223 dichloride (Xofigo®) policy at the provided URL to identify any changes to prior authorization requirements, coverage criteria, or billing procedures. Update billing protocols and staff training accordingly to ensure continued claim approval for this specialized cancer treatment.